

The usefulness of liquid-based cytology of bronchoalveolar lavage fluid combined with bronchial brush specimens in lung cancer diagnosis

Shanni Ma<sup>1,\*</sup> D. Xuechan Yu<sup>2,\*</sup>. Xiaoyan Iin<sup>1</sup>. Feng Qiu<sup>1</sup>, Xueqin Chen<sup>3</sup>, Ran Wang<sup>4</sup> and Chao Cao<sup>1</sup>

## Abstract

Objective: To explore the diagnostic value of liquid-based cytology (LBC) of bronchoalveolar lavage fluid (BALF) combined with bronchial brushing (BB).

Methods: One hundred patients with pulmonary masses or nodules found by chest computed tomography (CT) or X-ray before bronchoscopy or other diagnostic biopsy examinations were selected consecutively for this retrospective study. BALF and BB were performed for all patients. After conventional smear via BB, we mixed the BALF and BB samples in a prepared thin-layer bottle.

Results: The sensitivity of LBC of BALF combined with BB was noticeably higher than that of BB alone in the total sample group (65.15% vs. 32.84%, respectively). Similarly, in both the bronchoscopically visible group and invisible group, a higher sensitivity for LBC of BALF with BB vs BB alone (68.89% vs. 39.13%, respectively; 57.14% vs. 19.05%, respectively) was observed. Additionally, the negative predictive value of LBC of BALF with BB was higher than that with BB alone (58.56% vs. 42.31%; 61.29% vs. 44.73%; 53.47% vs. 37.83%; total sample vs visible vs invisible groups, respectively).

<sup>1</sup>Department of Respiratory and Critical Care Medicine, Ningbo First Hospital, Ningbo, Zhejiang, P. R. China <sup>2</sup>Ningbo University School of Medicine, Ningbo, Zhejiang, P. R. China

<sup>3</sup>Department of Traditional Medicine, Ningbo First Hospital, Ningbo, Zhejiang, P. R. China

<sup>4</sup>Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, P. R. China

\*These authors contributed equally to this study.

**Corresponding author:** 

Chao Cao, Department of Respiratory and Critical Care Medicine, Ningbo First Hospital, 59 Liuting Road, Ningbo 315000, China. Email: caocdoctor@163.com

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative  $\odot$   $\odot$ Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).

Journal of International Medical Research 2022, Vol. 50(11) 1-6 © The Author(s) 2022 Article reuse guidelines: sagepub.com/journals-permissions DOI: 10.1177/03000605221132708 journals.sagepub.com/home/imr



**Conclusion:** Regardless of whether lesions or nodules are bronchoscopically visible or invisible, LBC of BALF combined with BB may increase the diagnostic value over BB alone in lung cancer diagnosis.

### **Keywords**

Liquid-based cytology, bronchoalveolar lavage, bronchial brushing, lung cancer, diagnosis, bronchoscopy

Date received: 5 July 2022; accepted: 23 September 2022

# Introduction

Bronchoscopy is the most commonly used method in the diagnosis of lung cancer.<sup>1</sup> Cytological and histological methods for diagnosing lung cancer are routinely used during bronchoalveolar lavage (BAL) and bronchial brushing (BB) because these procedures are minimally invasive and easy to use.<sup>2,3</sup> Liquid-based cytology (LBC) is a technique that avoids poor cellular preservation caused by smear thickness, overlap, mucolytic substances, blood, and inflammatory cells. Therefore, LBC has been used to increase the diagnostic value of respiratory material, including bronchoalveolar lavage fluid (BALF) and BB.4 There have been several studies of the diagnostic yield of LBC in BALF and BB.<sup>5-9</sup> These studies showed that BALF and BB cytology are valuable tools for lung cancer diagnosis,<sup>3</sup> and LBC of BALF has higher diagnostic accuracy than that of a conventional direct smear.<sup>5</sup> For other respiratory materials, including BB, LBC can be a replacement for a conventional smear.<sup>7</sup> However, these methods will not work if samples and cells are scanty or sample concentration is not optimal. Our study group has proven that LBC of BALF combined with BB can increase the diagnostic value over BALF alone.<sup>10</sup> To increase the number of specimens for increasing the diagnostic value over BB alone, in the current study, we used the same method as in our previous study of mixing BB and BALF samples in an LBC-prepared bottle after completing the specimen sampling. To our knowledge, this method has not been reported previously. In summary, in this study, we compared the diagnostic value of LBC of BALF combined with BB to that of a BB smear alone.

## Materials and methods

## Patients and specimens

In this retrospective study, with verbal consent from the patients or their caregivers, 100 patients with pulmonary masses or nodules found by chest computed tomography (CT) or X-rays before bronchoscopy or other diagnostic biopsy examinations were consecutively enrolled from May 2015 to May 2016 in the Department of Respiratory and Critical Care Medicine of Ningbo First Hospital. The bronchoscopically visible group was defined as a mass or nodule that can be seen under bronchoscopy, and the invisible group was defined as a nonvisible mass or nodule. The patient's information and clinical characteristics were derived from their medical records and the hospital's registries. The diagnoses of the patients' lesions were confirmed via histological samples obtained via bronchoscopy, surgery, or percutaneous lung biopsy. This study was performed in accordance with the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for Lung Cancer.<sup>1</sup> Approval for this study was obtained from the Ningbo First Hospital Ethics Committee (No. 2021RS009). All patients' details have been de-identified. The reporting of this study conforms to the STROBE guidelines.<sup>11</sup>

# BALF and BB

These procedures have been described in our previous studies.<sup>10,12,13</sup> First, a straight brush (BC-202D-2010; Olympus, Tokyo, Japan) for BB was used for smearing the slides. Then, we put the brush into a BD CytoRich<sup>TM</sup> Red preservative (Cytyc Corporation, Boxborough, MA, USA) bottle. Finally, a BALF sample in 0.9% saline was added to fill the bottle.

## Statistical analysis

Clinical data, namely age, smoking years, and body mass index, were presented as mean  $\pm$ standard deviation (SD). Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were calculated to evaluate the diagnostic value in the total sample group, visible group, and invisible group. The statistical analyses were performed using GraphPad Prism 5.0 (GraphPad Software Inc., San Diego, CA, USA).

## Results

## Patient characteristics

Data for 100 patients (77 men and 23 women; age:  $63.13 \pm 8.88$  years) were analyzed in this study, and the clinical characteristics of these patients are summarized in Table 1. Using cytological and histological information, 67 patients were

Table I.	Clinical	characteristics	of the	recruited
participan	ts.			

· · ·	
	Participants (n = 100)
Age, years	
$Mean\pmSD$	$\textbf{63.13} \pm \textbf{8.88}$
Range	30–85
Sex, n (%)	
Male	77 (77%)
Female	23 (23%)
BMI, kg/m <sup>2</sup>	
$Mean\pmSD$	$\textbf{21.92} \pm \textbf{5.11}$
Smoking status, n (%)	
Smoker	62 (62%)
Non-smoker	38 (38%)
Pack-years	$\textbf{50.44} \pm \textbf{38.33}$
Lesion distribution, n (%)	
Visible	60 (60%)
Invisible	40 (40%)
Cell type, n (%)	
Malignant	67 (67%)
Squamous cell carcinoma	29 (29%)
Adenocarcinoma	25 (25%)
Small-cell lung cancer	8 (8%)
Other cancer type	5 (5%)
Benign	33 (33%)

SD, standard deviation; BMI, body mass index.

diagnosed with malignant lesions (29 squamous cell carcinomas, 25 adenocarcinomas, 8 small-cell lung cancers, and 5 other types of cancer), and 33 patients were diagnosed with benign lesions.

# Diagnostic value of BALF combined with BB vs BB alone

Using the final cytology and histology pathology results, the sensitivity, specificity, PPV, and NPV were calculated, and the results are presented in Table 2, Table 3, and Table 4. Table 2 shows that the sensitivity of LBC of BALF with BB was obviously higher than that with BB alone in the total sample group (65.15% vs. 32.84%, respectively). Similarly, in the visible group and invisible group, Table 3 and

Table 2. Diagnostic value of bronchoalveolar
lavage fluid (BALF) with bronchial brushing vs.
bronchial brushing alone.

	BALF with Bronchial Brushing	Bronchial Brushing Alone
Sensitivity (%)	65.15%	32.84%
Specificity (%)	100.00%	100.00%
PPV (%)	100.00%	100.00%
NPV (%)	58.56%	42.31%

 $\ensuremath{\mathsf{PPV}}$  , positive predictive value;  $\ensuremath{\mathsf{NPV}}$  , negative predictive value.

**Table 3.** Diagnostic value of bronchoalveolarlavage fluid (BALF) with bronchial brushing vs.bronchial brushing alone in visible lesions.

	BALF with Bronchial Brushing	Bronchial Brushing Alone
Sensitivity (%)	68.89%	39.13%
Specificity (%)	100.00%	100.00%
PPV (%)	100.00%	100.00%
NPV (%)	61.29%	44.73%

PPV, positive predictive value; NPV, negative predictive value.

Table 4 show a higher sensitivity of LBC of BALF with BB than that with BB alone (68.89% vs. 39.13%; 57.14 vs. 19.05%, respectively). Regardless of whether the lesions were visible or invisible, and compared with the total group, the NPV of LBC of BALF with BB was higher than that with BB alone (BALF with BB vs BB alone, respectively: 58.56% vs. 42.31%; 61.29% vs. 44.73%; 53.47% vs. 37.83% for total vs visible vs invisible groups, respectively). The specificity and PPV for LBC of BALF with BB were both 100% for all groups.

## Discussion

Cytological and histological methods are used with BAL and BB in patients with

**Table 4.** Diagnostic value of bronchoalveolarlavage fluid (BALF) with brush vs. brush alone ininvisible lesions.

	BALF with Brush	Brush Alone
Sensitivity (%)	57.14%	19.05%
Specificity (%)	100.00%	100.00%
PPV (%)	100.00%	100.00%
NPV (%)	53.47%	37.83%

PPV, positive predictive value; NPV, negative predictive value.

lung cancer. LBC is used routinely in BALF or BB because LBC helps remove exudates that contain mucus, blood, and inflammatory cells,14 as shown in previous studies.<sup>4,5,7,9</sup> Although samples are easily obtained with BALF or BB, and the procedures are minimally invasive, the diagnostic value of these methods for cancer is low.<sup>3,15</sup> In previous studies, the sensitivity of BALF for the diagnosis of lung cancer ranged from 29% to 57.3%,  $^{16-19}$  and the sensitivity of diagnosis was higher for lesions visible under bronchoscopy. The diagnostic yield of BB varies widely between studies, with a range of 18% to 87%.<sup>20</sup> Our study group previously mixed BALF and BB samples in a thin-layer prepared bottle to increase the diagnostic yield of BALF and BB. The results were published in a paper that demonstrated that the diagnostic value of LBC of BALF combined with BB was higher than that with BALF alone.<sup>10</sup> Therefore, we used the same method to compare the value of LBC of BALF with BB with that of BB alone, in this study. We concluded that LBC of BALF combined with BB may increase the diagnostic value of BB alone, regardless of whether the lesion is visible or invisible.

The main advantage of LBC is that cells spread in a thin layer without obscuring elements or resulting in cell overlap.<sup>21,22</sup> This characteristic helps improve the diagnostic yield of the cytological and histological samples. LBC of BALF has been confirmed to provide higher diagnostic accuracy than that with conventional direct smears of samples obtained with BB alone.<sup>5</sup> LBC combined with BB has been used routinely for samples obtained via bronchoscopy, and LBC can be considered a replacement for a conventional smear.<sup>4,7</sup> Similarly, our results confirmed that LBC of BALF combined with BB can improve the diagnostic value over BB alone.

Previous studies have shown that the diagnostic yield of BALF is similar to the yield with BB when lesions are bronchoscopically invisible.<sup>23-25</sup> However, data from our results revealed that LBC of BALF combined with BB may improve the diagnostic yield for both visible and invisible lesions. BB increased the cell yield if BAL failed to wash or recycle enough fluid. Furthermore, the thin layer of LBC maintains the cell morphology and interfering removes elements. Therefore, considering the results of our previous<sup>10</sup> and current studies, we conclude that LBC of BALF combined with BB improves the diagnostic value over BB or BALF alone.

The following limitation should be considered: BALF and BB with or without LBC are unsuitable for patient screening compared with using samples for gene detection. Deficient target cytological or histological samples is the main disadvantage in BALF with BB; therefore, in patients requiring further diagnostics or treatments, physicians should choose other biopsy procedures or methods.

# Conclusion

Regardless of whether lesions or nodules are bronchoscopically visible or invisible, LBC of BALF combined with BB specimens may increase the diagnostic value over BB alone in lung cancer. Considering the results of our previous and current studies, LBC of BALF combined with BB may be a replacement for BALF or BB alone.

### Data availability statement

All data used in this study are available from the corresponding author upon reasonable request.

### **Declaration of conflicting interests**

The Authors declare that there is no conflict of interest.

#### Funding

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

## **ORCID** iDs

Shanni Ma D https://orcid.org/0000-0003-1717-822X Xueqin Chen D https://orcid.org/0000-0002-1828-1985 Chao Cao D https://orcid.org/0000-0003-0429-7617

## References

- 1. Sakr L, Roll P, Payan MJ, et al. Cytologybased treatment decision in primary lung cancer: is it accurate enough? *Lung Cancer* 2012; 75: 293–299.
- Jones AM, Hanson IM, Armstrong GR, et al. Value and accuracy of cytology in addition to histology in the diagnosis of lung cancer at flexible bronchoscopy. *Respir Med* 2001; 95: 374–378.
- Zardawi IM, Blight A, Ling S, et al. Liquidbased vs. conventional cytology on respiratory material. *Acta Cytol* 2009; 53: 481–483.
- Astall E, Atkinson C, Morton N, et al. The evaluation of liquid-based 'Cyto-SED' cytology of bronchioalveolar lavage specimens in the diagnosis of pulmonary neoplasia against conventional direct smears. *Cytopathology* 2003; 14: 143–149.
- Rana DN, O'Donnell M, Malkin A, et al. A comparative study: conventional preparation and ThinPrep 2000 in respiratory cytology. *Cytopathology* 2001; 12: 390–398.

- Kobayashi Y, Uehara T and Ota H. Liquidbased thin-layer cytology can be routinely used in samples obtained via fiberoptic bronchoscope. *Acta Cytol* 2011; 55: 69–78.
- Kim S and Owens CL. Analysis of ThinPrep cytology in establishing the diagnosis of small cell carcinoma of lung. *Cancer* 2009; 117: 51–56.
- Wang HH, Sovie S, Trawinski G, et al. ThinPrep processing of endoscopic brushing specimens. *Am J Clin Pathol* 1996; 105: 163–167.
- Cao C, Yu X, Zhu T, et al. Diagnostic role of liquid-based cytology of bronchial lavage fluid in addition to bronchial brushing specimens in lung cancer. *Tumori* 2020; 107: 325–328. 300891620960218.
- Wood DE, Kazerooni E, Baum SL, et al., National comprehension cancer network. Lung cancer screening, version 1.2015: featured updates to the NCCN guidelines. *J Natl Compr Canc Netw* 2015; 13: 23–34.
- Von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *Ann Intern Med* 2007; 147: 573–577.
- Cao C, Sun SF, Lv D, et al. Utility of VEGF and sVEGFR-1 in bronchoalveolar lavage fluid for differential diagnosis of primary lung cancer. *Asian Pac J Cancer Prev* 2013; 14: 2443–2446.
- Cao C, Chen ZB, Sun SF, et al. Evaluation of VEGF-C and tumor markers in bronchoalveolar lavage fluid for lung cancer diagnosis. *Sci Rep* 2013; 3: 3473.
- Hees K and Lebeau PB. Comparison of conventional and ThinPrep preparations of mucoid cytology samples. *Diagn Cytopathol* 1995; 12: 181–185.
- Ost DE, Ernst A, Lei X, et al. Diagnostic yield and complications of bronchoscopy for peripheral lung lesions. Results of the

AQuIRE Registry. *Am J Respir Crit Care Med* 2016; 193: 68–77.

- Bezel P, Tischler V, Robinson C, et al. Diagnostic value of bronchoalveolar lavage for diagnosis of suspected peripheral lung cancer. *Clin Lung Cancer* 2016; 17: e151–e156.
- Thakur A, Bakshi P, Kaur G, et al. Liquidbased and conventional cytology for bronchial washings/bronchoalveolar lavages in the diagnosis of malignancy - an institutional experience. J Cytol 2017; 34: 127–132.
- Schreiber G and McCrory DC. Performance characteristics of different modalities for diagnosis of suspected lung cancer: summary of published evidence. *Chest* 2003; 123: 115S–128S.
- Ding W, Yue W and Fu Y. [The current research feature and prospect of bronchoalveolar lavage in diagnosing lung cancer]. *Zhongguo Fei Ai Za Zhi* 2010; 13: 370–374.
- Chen CC, Bai CH, Lee KY, et al. Evaluation of the diagnostic accuracy of bronchial brushing cytology in lung cancer: a metaanalysis. *Cancer Cytopathol* 2021; 129: 739–749.
- Howell LP, Davis RL, Belk TI, et al. The AutoCyte preparation system for gynecologic cytology. *Acta Cytol* 1998; 42: 171–177.
- Scimia M. ThinPrep pap test: a platform for gynecological diagnosis. *Adv Clin Path* 2001; 5: 183–184.
- Mak VH, Johnston ID, Hetzel MR, et al. Value of washings and brushings at fibreoptic bronchoscopy in the diagnosis of lung cancer. *Thorax* 1990; 45: 373–376.
- 24. Lam WK, So SY, Hsu C, et al. Fibreoptic bronchoscopy in the diagnosis of bronchial cancer: comparison of washings, brushings and biopsies in central and peripheral tumours. *Clin Oncol* 1983; 9: 35–42.
- Wong PC, Lee J, Lam FM, et al. Fibreoptic bronchoscopy in the diagnosis of lung cancer. *Monaldi Arch Chest Dis* 1999; 54: 394–398.